Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Sep 1;143(9):759-768.
doi: 10.1001/jamaophthalmol.2025.2489.

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis

Gabriella R Natividade  1   2   3 , Bernardo F Spiazzi  2   4 , Matheus W Baumgarten  3 , Caroline Bassotto  3 , Afonso A Pereira  3 , Bruna L Fraga  1 , Bruno G Scalco  1 , Nicole R Mattes  1 , Daniel Lavinsky  1   2   5 , Caroline K Kramer  6 , Fernando Gerchman  1   2   3
Affiliations
Meta-Analysis

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis

Gabriella R Natividade et al. JAMA Ophthalmol. .

Abstract

Importance: Semaglutide is a widely used treatment for diabetes and obesity, offering considerable cardiovascular benefit. However, its association with ocular adverse events remains uncertain.

Objective: To assess the incidence of eye disorders, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy (NAION) in adults treated with semaglutide.

Data sources: A comprehensive electronic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted on April 10, 2025, without date restrictions.

Study selection: Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events.

Data extraction and synthesis: Descriptive synthesis of the included studies was performed. The random-effects model using the inverse variance method was used to summarize the odds ratio (OR) for eye disorders and diabetic retinopathy. Peto OR with a fixed-effects model was applied for NAION. Risk of bias was assessed with the RoB 2.0 tool and quality of evidence with GRADE. Trial sequential analysis (TSA) was performed to determine whether the available data were sufficient for definitive conclusions.

Main outcomes and measures: The primary outcomes included the number of patients experiencing an ocular adverse event, diabetic retinopathy, or NAION. Subgroup analyses were conducted based on follow-up duration, comparator type, and primary baseline condition.

Results: A total of 78 trials with 73 640 participants were included. Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17). Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02). Overall risk of bias was low. TSA provided evidence that the sample size was sufficient to avoid missing alternative results for diabetic retinopathy but not for NAION.

Conclusions and relevance: These findings suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION. Further studies with larger sample sizes and adequate evaluation of NAION are warranted to clarify this potential risk.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Natividade reported a research assistant scholarship from CAPES (PRINT program 2024). Dr Fraga reported grants from Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (research assistant scholarship) outside the submitted work. Dr Kramer reported grants from Boehringer Ingelheim outside the submitted work. Dr Gerchman reported grants from Financiamento e Incentivo à Pesquisa of Pesquisa of Hospital de Clínicas de Porto Alegre during the conduct of the study and personal fees from Novo Nordisk, Eli Lilly, Merck, and Abbott and grants from National Council for Scientific and Technological Development outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Marso SP, Bain SC, Consoli A, et al. ; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141 - DOI - PubMed
    1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. ; SELECT Trial Investigators . semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563 - DOI - PubMed
    1. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296 - DOI - PMC - PubMed
    1. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897. doi: 10.1111/dom.13172 - DOI - PMC - PubMed
    1. Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M. Non-arteritic anterior ischemic optic neuropathy (na-aion): a comprehensive overview. Vision. 2023;7(4):72. doi: 10.3390/vision7040072 - DOI - PMC - PubMed

MeSH terms